Tue, Sep 30, 2014, 6:41 AM EDT - U.S. Markets open in 2 hrs 49 mins


% | $
Quotes you view appear here for quick access.

Weatherford International plc Message Board

ddbikessamsara 4 posts  |  Last Activity: Jul 15, 2014 12:16 PM Member since: Oct 5, 2004
  • Reply to

    Balance sheet

    by garyc732 Jul 15, 2014 8:58 AM
    ddbikessamsara ddbikessamsara Jul 15, 2014 12:16 PM Flag

    Seems like a massive over-reaction to me. The market and outlook are unchanged if not significantly improved by this move and losing a measly 28 cent annual dividend certainly doesn't justify a $2.00 drop ire price. I'm in for a long term hold on this one.

    Sentiment: Strong Buy

  • Reply to

    Buying Opportunity?

    by chrispop562005 Jul 7, 2014 11:02 AM
    ddbikessamsara ddbikessamsara Jul 7, 2014 4:37 PM Flag

    I bought more today. I just reviewed the recent conference call transcript again on Seeking Alpha. I just can't see that the train has really derailed. A hiccup, yes. But the overall direction is positive and the main growth drivers are as strong as ever. 2015 could be another big growth year after regrouping this year and if some of the really big deals they are pursuing go through this stock could be right back over $20. Upside far outweighs the downside. Picking the perfect entry point is virtually impossible and if you have a long-term perspective - as I do - buying here is a pretty good bet to pay off handsomely in a year or so.

    Sentiment: Strong Buy

  • ddbikessamsara by ddbikessamsara Jul 1, 2014 11:36 AM Flag

    I have a friend who is a lifelong Type 1 and who has endured tens of thousands of shots in her lifetime of 57 years. She has suffered many scary, wild swings in blood sugar from trying to get her mealtime regimen figured out. I saw her yesterday evening and mentioned that Afrezza has just been approved. She had sort of heard about it but didn't follow things that closely. When I told her about the rapid-in rapid-out performance and the inhaled feature her eyes lit up like a kid before Christmas. She asked me in an incredulous tone "You mean no more shots?". She uses the Minimed pump and was surprised that Al Mann had been the driving force behind that - which was a huge boon to her when it was introduced.

    So a long time diabetic who as the lamesters would claim is "used to shots and not interested in trying something new" was so excited about the prospect of no more shots she could barely contain herself. The better curve of insulin around mealtimes also had her really excited.

    This is just one example. DO NOT believe that the no shot feature is not a huge factor because it is. People on this board probably know a lot more about Afrezza than actual diabetics because we follow things so closely while people like my friend are just busy with their lives and might hear about something like this but not really investigate since it was not available anyway.

    Once Afrezza is actually on the market and being advertised it will not take long to build awareness and demand. Word - of - mouth will be a huge driver as well, just like me mentioning it to my friend. Once it is available and in use the real life success stories just like Affrezzauser's will be rolling in on blogs etc. Given time - and it will take time, anyone saying "We are going to $50 in a week" is just being silly - this can grow into a major, mainstream daily regimen for many millions of patients. I'm long and strong and holding for years.

    Sentiment: Strong Buy

  • ddbikessamsara by ddbikessamsara Jun 30, 2014 2:05 PM Flag

    Afrezza is a meal-time insulin. I see 400 million diabetics around the world, 3 meals a day. That is a potential 1.2 BILLION uses per DAY. Hardly a "niche" market as many news stories are blurting. Even a tiny percent of that represents breath-takingly gargantuan sales. The market is there - all they have to do is execute a good marketing campaign. It will take time to grow the distribution channels, of course. But if the results are as good as advertised the speed and overall efficacy of the product will capture a significant market share all over the world. The news stories only focus on the US market but the diabetes issue is global and growing.

    Sentiment: Strong Buy

21.23-0.08(-0.38%)Sep 29 4:05 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.